Recognition

Celgene-Juno Deal Honored as “Alliance of the Year”

January 19, 2016

IN VIVO

Premier biopharma publication recognizes deal to help fight cancer and autoimmune diseases.

IN VIVO honored Celgene’s US$1 billion collaboration with Juno Therapeutics with its “Alliance of the Year” award for 2015. The transaction marks the highest ever upfront payment for a biopharma licensing deal, according to The Pink Sheet.

Latham & Watkins represented Juno Therapeutics in the agreement with a corporate team led by partners Judith Hasko and Robert Koenig.

Hasko, the firm’s Life Science Transactions global Chair, noted: “This groundbreaking and novel transaction was designed to enable both companies to discover and develop innovative cancer and immunology therapeutics."

Endnotes

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.